MAZE
Maze Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$26.21
+1.31%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$0.79
- Revenue estimate
- $333.3K
Latest reported
- Last report date
- Aug 12, 2026
- EPS actual
- -$0.76
- EPS estimate
- -$0.72
- Revenue actual
- —
- Revenue estimate
- $2.9M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 2
- EPS misses (12Q)
- 3
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +2.8%
- Revenue beats (12Q)
- 1
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026